This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: The University of Tokyo. Active years: 2011-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2013
Title: Innovations in Blood Cell Preparation by Hidekazu Nishiki-I
Introduction
Hidekazu Nishiki-I is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of regenerative medicine, particularly in the preparation of blood cells from induced pluripotent stem (iPS) cells. With a total of 2 patents, his work is paving the way for advancements in blood cell therapies.
Latest Patents
Nishiki-I's latest patents focus on methods for efficiently preparing blood cells, such as mature megakaryocytes and platelets, from iPS cells. One of his notable inventions is a method that utilizes a sac-like structure to enclose hematopoietic progenitor cells. This structure is created by inoculating iPS cells onto feeder cells and culturing them under specific conditions that promote differentiation. Additionally, he has developed a method for producing various types of blood cells without the need for the sac-like structure, showcasing the versatility of his approaches.
Career Highlights
Nishiki-I is affiliated with The University of Tokyo, where he conducts his research and development in the field of stem cell technology. His innovative methods have the potential to revolutionize the way blood cells are produced, which is crucial for various medical applications, including transfusions and treatments for blood disorders.
Collaborations
He has collaborated with notable researchers in the field, including Hiromitsu Nakauchi and Koji Eto. These collaborations have further enhanced the impact of his work and contributed to the advancement of stem cell research.
Conclusion
Hidekazu Nishiki-I's contributions to the preparation of blood cells from iPS cells represent a significant advancement in regenerative medicine. His innovative methods and collaborative efforts are likely to lead to breakthroughs in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
